J&J Medical Connect
CAPLYTA®

(lumateperone)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

CAPLYTA - Effect on Anxiety

Last Updated: 11/03/2026

SUMMARY

  • CAPLYTA is indicated for: treatment of schizophrenia in adults; treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate; and adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.1 CAPLYTA is not approved for the treatment of generalized anxiety disorder.
  • Durgam et al (2025)2 conducted a 6-week, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, phase 3 study (Study 501) to assess the efficacy and safety of CAPLYTA 42 mg adjunctive to antidepressant therapy (ADT) in patients with MDD who had an inadequate response to ADT.
    • Generalized Anxiety Disorder-7 item (GAD-7) Total score least squares (LS) mean change from baseline to day 43 was -4.7 (standard error [SE], 0.26) for CAPLYTA 42 mg+ADT (n=241) vs -3.1 (0.26) for placebo+ADT (n=243) in the intent-to-treat (ITT) population.
  • Sachs et al (2026)3 conducted a post hoc exploratory analysis of Study 501 to evaluate the efficacy of adjunctive treatment of CAPLYTA in patients with MDD and anxious distress (CAPLYTA 42 mg+ADT, n=109; placebo+ADT, n=98).
    • GAD-7 Total score LS mean change from baseline to day 43 was -5.5 (SE, 0.42) for CAPLYTA 42 mg+ADT (n=109) vs -2.3 (0.43) for placebo+ADT (n=98) in patients with anxious distress (mITT population).4

PRODUCT LABELING

CAPLYTA is an atypical antipsychotic indicated for: treatment of schizophrenia in adults; treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate; and adjunctive therapy with antidepressants for the treatment of MDD in adults.1 

CLINICAL DATA

Phase 3 Study

Durgam et al (2025)2 conducted a randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study (Study 501) to assess the efficacy and safety of CAPLYTA adjunctive to ADT in patients with MDD who had an inadequate response to ADT. Patients were randomized (1:1) to receive either CAPLYTA 42 mg (n=242) or placebo (n=243) as adjunctive treatment to ADT for 6 weeks; this was followed by a 1-week safety follow-up period (See Figure: Study Design for Study 501).

Study Design for Study 5015

Study design diagram for Study 501 showing 485 participants randomized after a screening period of up to 14 days to a 6-week double-blind treatment period. Received either CAPLYTA 42 mg once daily + ADT (n=242) or placebo + ADT (n=243) with a 1-week safety follow-up after treatment.

Abbreviations: ADT, antidepressant therapy; ET, early termination.
aEligible patients who completed 6 weeks of double-blind treatment and provided informed consent to rollover into the open-label safety study would not have entered the safety follow-up period.

  • CAPLYTA+ADT showed a statistically significant reduction in the GAD-7 Total score compared to placebo+ADT.2
  • The baseline mean±standard deviation (SD) GAD-7 Total score was 9.9±5.00 for CAPLYTA 42 mg+ADT and 9.6±5.03 for placebo+ADT.
    • In the ITT population, the LS mean (SE) change from baseline to day 22 was -3.2 (0.26) for CAPLYTA 42 mg+ADT (n=241) vs -2.2 (0.26) for placebo+ADT (n=243). The LS mean difference was -1.0 (95% confidence interval [CI]: -1.65 to -0.28).5
    • In the ITT population, the LS mean (SE) change from baseline to day 43 was -4.7 (0.26) for CAPLYTA 42 mg+ADT (n=241) vs -3.1 (0.26) for placebo+ADT (n=243). The LS mean difference was -1.6 (95% CI: -2.31 to -0.93), with an effect size of -0.43.2

Sachs et al (2026)3 conducted a post hoc exploratory analysis of Study 501 to evaluate the efficacy of adjunctive treatment of CAPLYTA in patients with MDD and anxious distress (CAPLYTA 42 mg+ADT, n=109; placebo+ADT, n=98).

  • The baseline mean±SD GAD-7 Total score was 11.9±4.4 for CAPLYTA 42 mg+ADT and 11.3±4.2 for placebo+ADT.
    • In patients with anxious distress (mITT population), the LS mean (SE) change from baseline to day 43 was -5.5 (0.42) for CAPLYTA 42 mg+ADT (n=109) vs -2.3 (0.43) for placebo+ADT (n=98). The LS mean difference was -3.2 (95% CI: -4.29 to -2.19), with an effect size of 0.88.4

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 1 October 2026.

 

References

1 CAPLYTA (lumateperone) [Prescribing Information]. Titusville, NJ: Intra-Cellular Therapies, Inc; https://www.intracellulartherapies.com/docs/caplyta_pi.pdf
2 Durgam S, Earley WR, Kozauer SG, et al. Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. J Clin Psychiatry. 2025;86(4):25m15848.  
3 Sachs GS, Durgam S, Earley WR, et al. Lumateperone as adjunctive therapy in patients with major depressive disorder and anxious distress: post hoc analysis of a phase 3, randomized, double-blind trial. J Clin Psychiatry. 2026;87(3):26m16409.  
4 Sachs GS, Durgam S, Earley WR, et al. Supplement to: Lumateperone as adjunctive therapy in patients with major depressive disorder and anxious distress: post hoc analysis of a phase 3, randomized, double-blind trial. J Clin Psychiatry. 2026;87(3):26m16409.  
5 Data on File. CAPLYTA. Clinical Study Report of Study 501. Intra-Cellular Therapies, Inc; 2024.  

Would you like to clear and leave your conversation? Message history will be lost.